MDNA Life Sciences announces that it has entered into an exclusive license agreement with its first international commercial partner.
News
MDNA Life Sciences and University of Oxford to collaborate to develop a Mitochondrial Biomarker blood-based diagnostic for endometriosis
MDNA Life Sciences has entered into a collaboration agreement with the University of Oxford to further the development and validation of MDNA’s non-invasive blood-based test for endometriosis.
Mitomic Prostate Core Test™ significantly reduces unnecessary biopsies, improves cancer detection, new study says
A clinical study published in the American Health & Drug Benefits journal describes the Mitomic Prostate Core Test’s impact on patient management and the biopsy decision-making process.
MDNA set to launch slew of new blood-based cancer tests
The diagnostics game has changed dramatically over the past 15 years. Old-school companies placed their bets on high-volume, low-margin tests, but today’s molecular diagnostics players are all about value proposition. The market is hungry for simple tests that impact patient outcomes while also taking costs out of the system.
Continue reading “MDNA set to launch slew of new blood-based cancer tests”
MDNA Life Sciences Appoints New Management Team Members to Lead Development and Commercialization of Mitochondrial Diagnostic Pipeline
Chris Mitton Appointed Chief Executive Officer; Jack Riccardi Appointed Chief Financial Officer.